Resona Asset Management Co. Ltd. Reduces Holdings in Moderna, Inc. $MRNA

Resona Asset Management Co. Ltd. lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 96.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,908 shares of the company’s stock after selling 98,778 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Moderna were worth $106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in MRNA. S Bank Fund Management Ltd purchased a new position in Moderna in the first quarter worth approximately $25,000. TD Private Client Wealth LLC raised its position in Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares during the period. Atlantic Union Bankshares Corp acquired a new position in shares of Moderna in the 2nd quarter valued at $26,000. SVB Wealth LLC purchased a new position in shares of Moderna during the 1st quarter worth $28,000. Finally, Whittier Trust Co. acquired a new stake in shares of Moderna during the 2nd quarter worth about $28,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on MRNA. Leerink Partners decreased their target price on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research report on Friday, August 22nd. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research note on Thursday, October 23rd. Citigroup decreased their price objective on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Thursday, October 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Finally, Morgan Stanley boosted their target price on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $36.14.

Moderna Stock Performance

Shares of MRNA stock opened at $26.71 on Thursday. Moderna, Inc. has a fifty-two week low of $23.04 and a fifty-two week high of $48.92. The company has a 50 day moving average price of $25.92 and a 200 day moving average price of $27.11. The stock has a market capitalization of $10.44 billion, a P/E ratio of -3.31 and a beta of 2.02.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. During the same period in the prior year, the business earned $0.03 EPS. The firm’s quarterly revenue was down 45.4% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.